Evaluating an Expanding Prodrug Platform for Controlled Drug Delivery

The development of new strategies to improve drug delivery has the potential to significantly improve patient outcomes. Ripple Therapeutics has developed a new approach to developing implants based on a discovery that prodrugs (an inactive version of a drug) can be processed into an implant without the use of a polymer to hold the implant together and control the release rate of the drug. This project will determine if these implants can predictably control drug release and the safety of the prototype implant materials will be confirmed. The successful completion of this project will provide Ripple with data to advance this product and accelerate its clinical program.

Faculty Supervisor:

Heather Sheardown

Student:

Partner:

Ripple Therapeutics

Discipline:

Engineering

Sector:

Professional, scientific and technical services

University:

McMaster University

Program: